These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 19397418)

  • 1. Influenza A (H5N1) pandemic prototype vaccine Fluval.
    Vajo Z
    Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children.
    Vajo Z; Kosa L; Szilvasy I; Pauliny Z; Bartha K; Visontay I; Kis A; Tarjan I; Rozsa N; Jankovics I
    Pediatr Infect Dis J; 2008 Dec; 27(12):1052-6. PubMed ID: 18978514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
    Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of vaccines against influenza A virus (H5N1).
    Li WC; Huang YC
    Chang Gung Med J; 2007; 30(4):294-304. PubMed ID: 17939259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains.
    Fazekas G; Martosne-Mendi R; Jankovics I; Szilvasy I; Vajo Z
    Clin Vaccine Immunol; 2009 Apr; 16(4):437-43. PubMed ID: 19020111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
    Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
    Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for developing vaccines against H5N1 influenza A viruses.
    Horimoto T; Kawaoka Y
    Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pandemic H5N1 influenza vaccine development: an update.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
    Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
    J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.
    Leroux-Roels I; Borkowski A; Vanwolleghem T; Dramé M; Clement F; Hons E; Devaster JM; Leroux-Roels G
    Lancet; 2007 Aug; 370(9587):580-9. PubMed ID: 17707753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.
    Leroux-Roels G
    Expert Opin Biol Ther; 2009 Aug; 9(8):1057-71. PubMed ID: 19555313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations.
    Miyaki C; Quintilio W; Miyaji EN; Botosso VF; Kubrusly FS; Santos FL; Iourtov D; Higashi HG; Raw I
    Vaccine; 2010 Mar; 28(13):2505-9. PubMed ID: 20123051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEW technologies for meeting the global demand for pandemic influenza vaccines.
    Fedson DS
    Biologicals; 2008 Nov; 36(6):346-9. PubMed ID: 18715803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.
    Jones T
    Curr Opin Mol Ther; 2009 Jun; 11(3):337-45. PubMed ID: 19479667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emulsion-based adjuvants for influenza vaccines.
    Vogel FR; Caillet C; Kusters IC; Haensler J
    Expert Rev Vaccines; 2009 Apr; 8(4):483-92. PubMed ID: 19348563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.